Moderna (MRNA) Current Assets (2017 - 2026)

Moderna (MRNA) has 10 years of Current Assets data on file, last reported at $5.8 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $5.8 billion, down 14.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 billion (down 14.72% YoY), and the FY2025 annual result was $6.5 billion, down 19.2% from the prior year.
• Current Assets fell to $5.8 billion in Q1 2026 per MRNA's latest filing, from $6.5 billion in the prior quarter.
• Over five years, Current Assets peaked at $16.4 billion in Q1 2022 and troughed at $5.8 billion in Q1 2026.
• A 5-year average of $10.0 billion and a median of $9.7 billion in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets jumped 39.71% in 2022, then tumbled 36.12% in 2025.
• A 5-year view of Current Assets shows it stood at $13.4 billion in 2022, then fell by 23.13% to $10.3 billion in 2023, then retreated by 21.56% to $8.1 billion in 2024, then dropped by 19.2% to $6.5 billion in 2025, then decreased by 11.83% to $5.8 billion in 2026.
• Business Quant data shows MRNA's Current Assets at $5.8 billion in Q1 2026, $6.5 billion in Q4 2025, and $6.6 billion in Q3 2025.